About
Profile
We provide sustainable supply chain, product, and patient solutions that lower total costs and improve quality of care across the continuum of care.
Headquarters
Intraday
High
-
Low
-
52-week
High
-
Low
-
OMI
...
Available for logged in users only.
The multiple price alert feature will smartly add or remove $1 if your alert was hit.
It's only available if you are logged in, a V.I.P. member or if you are using the AI chrome extension.
Contact us via Twitter if you are interested in trying it out.
- Nanobiotix, Owens & Minor top healthcare gainers; Soligenix, DermTech among losers
- Owens & Minor beats Q1 top and bottom line estimates; revises FY23 outlook
- Owens & Minor Q1 2023 Earnings Preview
- Owens & Minor Non-GAAP EPS of $0.28 misses by $0.12, revenue of $2.55B beats by $90M, introduces FY23 outlook
- Owens & Minor Q4 2022 Earnings Preview
- Owens & Minor Non-GAAP EPS of $0.41 beats by $0.02, revenue of $2.5B beats by $100M
- Owens & Minor Q3 2022 Earnings Preview
- Owens & Minor cut at Citi on increased risk, lack of management clarity
- Owens & minor slips pre market on lowering FY guidance, announces executive leadership team changes
- Citi picks best Buy and Sell stocks in all sectors, leaning to quality and momentum
- Owens & Minor reports Q2 earnings miss; narrows FY22 outlook
- Owens & Minor Q2 2022 Earnings Preview
- Owens & Minor awarded $1.125B Defense Department contract modification
- Owens & Minor Non-GAAP EPS of $0.96 beats by $0.14, revenue of $2.41B beats by $100M
- Owens & Minor Q1 2022 Earnings Preview
- Owens & Minor resumed with a buy at Citi as Apria acquisition strengthens DME position
- Owens & Minor prices upsized senior notes offering
- Owens & Minor to raise $500M through debt offering
- Apria GAAP EPS of $0.44 misses by $0.02, revenue of $296.5M beats by $3.48M
- Owens & Minor projects lower than expected guidance despite Q4 earnings beat
